A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

← catalyst calendar

NCT04973605 · readout ≤ 103 d

Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

246estimated

Sites

Countries

Australia, Brazil, Canada +10

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2021-09-16

actual

When the study began enrolling

Primary completion

Nov 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Nov 2026

estimated

The whole study's end, after follow-up

First posted

2021-07-22

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-07

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Relapsed/Refractory Multiple Myeloma

Interventions

Drug: Sonrotoclax — also filed as BGB-11417
Drug: Dexamethasone
Drug: Carfilzomib
Drug: Daratumumab
Drug: Pomalidomide

Primary outcomes

what the primary-completion date above is the date OF

Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)

measured Up to 28 days

Part 1 And 2: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events Leading to Discontinuation and Adverse Events of Special Interest (AESIs).

measured Up to 30 days after last dose of study drug

Part 2: Overall response rate (ORR) as Assessed by Investigator

measured Approximately 4 years

Part 2: Very Good Partial Response (VGPR) or Better Response Rate as Assessed by Investigator

measured Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]

Part 2: Complete Response (CR) or Stringent Complete Response (sCR) as Assessed by Investigator

measured Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])

Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed